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Abstract
Hydrogen sulfide (H2S), a gas with the characteristic odor of rotten
eggs, is known for its toxicity and as an environmental hazard,
inhibition of mitochondrial respiration resulting from blockade of
cytochrome c oxidase being the main toxic mechanism. Recently,
however, H2S has been recognized as a signaling molecule of the
cardiovascular, inflammatory and nervous systems, and therefore,
alongside nitric oxide and carbon monoxide, is referred to as the
third endogenous gaseous transmitter. Inhalation of gaseous H2S
as well as administration of inhibitors of its endogenous production
and compounds that donate H2S have been studied in various
models of shock. Based on the concept that multiorgan failure
secondary to shock, inflammation and sepsis may represent an
adaptive hypometabolic reponse to preserve ATP homoeostasis,
particular interest has focused on the induction of a hibernation-like
suspended animation with H2S. It must be underscored that
currently only a limited number of data are available from clinically
relevant large animal models. Moreover, several crucial issues
warrant further investigation before the clinical application of this
concept. First, the impact of hypothermia for any H2S-related organ
protection remains a matter of debate. Second, similar to the friend
and foe character of nitric oxide, no definitive conclusions can be
made as to whether H2S exerts proinflammatory or anti-inflam-
matory properties. Finally, in addition to the question of dosing and
timing (for example, bolus administration versus continuous
intravenous infusion), the preferred route of H2S administration
remains to be settled – that is, inhaling gaseous H2S versus intra-
venous administration of injectable H2S preparations or H2S
donors. To date, therefore, while H2S-induced suspended anima-
tion in humans may still be referred to as science fiction, there is
ample promising preclinical data that this approach is a fascinating
new therapeutic perspective for the management of shock states
that merits further investigation.
Introduction
Hydrogen sulfide (H2S), a colorless, flammable and water-
soluble gas with the characteristic odor of rotten eggs, has
been known for decades because of its toxicity and as an
environmental hazard [1,2]. Inhibition of mitochondrial
respiration – more potent than that of cyanide [3] – resulting
from blockade of cytochrome c oxidase is the main mecha-
nism of H2S toxicity [4,5]. During recent years, however, H2S
has been recognized as an important signaling molecule of
the cardiovascular system, the inflammatory system and the
nervous system. Alongside nitric oxide (NO) and carbon
monoxide, therefore, H2S is now known as the third
endogenous gaseotransmitter [1,6].
Since H2S is a small ubiquitous gaseous diffusible molecule,
its putative interest for intensive care research is obvious.
Consequently, inhibitors of its endogenous production as
well as compounds that donate H2S have been studied in
various models of shock resulting from hemorrhage [7-9],
ischemia/reperfusion [10-18], endotoxemia [19-21], bacterial
sepsis [22-25] and nonmicrobial inflammation [26-29] –
which, however, yielded rather controversial data with respect
to the proinflammatory or anti-inflammatory properties of H2S.
The present article reviews the current literature on the
therapeutic potential of H2S, with a special focus on clinically
relevant studies in – if available – large animal models.
Biological chemistry
In mammals, H2S is synthesized from the sulfur-containing
amino acid L-cysteine by either cystathionine-β-synthase or
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cystathionine-γ-lyase, both using pyridoxal 5′-phosphate
(vitamin B6) as a cofactor [30-32]. This synthesis results in
low micromolar H2S levels in the extracellular space, which
can be rapidly consumed and degraded by various tissues.
Similarly to NO and carbon monoxide, H2S is a lipophilic
compound that easily permeates cell membranes without
using specific transporters. Via direct inhibition, NO as well
as carbon monoxide are involved in the regulation of
cystathionine-β-synthase, but not cystathionine-γ-lyase, which
can be activated by lipopolysaccharide (LPS) [1,6].
There are three known pathways of H2S degradation: mito-
chondrial oxidation to thiosulfate, which is further converted
to sulfite and sulfate; cytosolic methylation to dimethylsulfide;
and sulfhemoglobin formation after binding to hemoglobin
[6]. Similar to NO and carbon monoxide, H2S can also bind
to hemoglobin – which was therefore termed the common
sink for the three gaseous transmitters [33]. Consequently,
saturation with one of these gases might lead to enhanced
plasma concentrations and, subsequently, to biological effects
of the other gases [1]. Table 1 summarizes the physico-
chemistry of H2S in mammalian tissues.
Mechanisms of H2S
H2S exerts its effects in biological systems through a variety
of interrelated mechanisms (for a review see [1]). Our current
knowledge of the biology of H2S predominantly stems from in
vitro studies in various cell and isolated organ systems, either
using cystathionine-γ-lyase inhibitors such as D,L-propargyl-
glycine (PAG) and β-cyanoalanine, or administration of H2S
gas or H2S donors such as sodium disulfide (Na2S) and
sodium hydrogen sulfide (NaHS). While high (high micro-
molar to millimolar) levels are invariably accompanied with
cytotoxic effects [34] – which result from free radical genera-
tion, glutathione deletion, intracellular iron release and pro-
apoptotic action through both the death receptor and
mitochondrial pathways [35] – lower (low micromolar) levels
have been shown to exert either cytoprotective (antinecrotic
or antiapoptotic) effects [10-13,36] or proapoptotic proper-
ties [37-39], depending on the cell type and on the experi-
mental conditions.
Cytochrome c oxidase, a component of the oxidative
phosphorylation machinery within the mitochondrium, is one
intracellular target of H2S [4,5]. Both the toxic effects of H2S
as well as the induction of a so-called “suspended animation”
[40,41] are referred to in this inhibition of mitochondrial
respiration [42,43], and thus may represent a possible mecha-
nism for the regulation of cellular oxygen consumption [44].
Activation of potassium-dependent ATP channels is another
major mechanism of H2S, which in turn causes vasodilation,
preconditioning against ischemia/reperfusion injury and
myocardial protection [45]. Various findings support this
concept [1,6,46]: potassium-dependent ATP channel
blockers (sulfonylurea derivates – for example, glibenclamide)
attenuated the H2S-induced vasodilation both in vivo and in
vitro  [47,48], and stimulation of potassium-dependent ATP
channels was demonstrated in the myocardium, pancreatic β
cells, neurons and the carotid sinus [6]. Moreover, gliben-
clamide reversed the otherwise marked Na2S-related
increase of the hepatic arterial buffer response capacity that
counteracts reduction of portal venous flow, whereas PAG
decreased this compensatory mechanism [49].
An endothelium-dependent effect seems to contribute to
these vasodilatory properties: in human endothelial cells, H2S
caused direct inhibition of the angiotensin-converting enzyme
[50], and, finally, H2S can enhance the vasorelaxation
induced by NO [51,52]. The interaction between H2S and
NO with respect to vascular actions is, however, fairly
complex: low H2S concentrations may cause vasoconstric-
tion as a result of an attenuated vasorelaxant effect of NO
due to scavenging of endothelial NO and formation of an
inactive nitrosothiol [52-54]. The local oxygen concentration
apparently assumes importance for the vasomotor properties
of H2S as well [55]: while H2S had vasodilator properties at
40 μM oxygen concentration (that is, an oxygen partial
Table 1
Physicochemistry and biology of hydrogen sulfide
Environmental toxicology Toxic gas originating from sewers, swamps, and putrefaction
Endogenous sources Synthesized in various tissues from L-cysteine by cystathionine-β-synthase or cystathionine-γ-lyase
Pharmacological inhibitors D,L-propargylglycine and β-cyanoalanine (limited selectivity, unspecific side-effects)
Elimination kinetics Half-life within minutes; metabolites comprise thiosulfate, sulfite, and sulfate
Receptors and targets Potassium-dependent ATP channels (others?); cytochrome c oxidase
Vascular effects Vasodilatation or vasoconstriction (depending on local oxygen concentration)
Biological effects Radical scavenging, upregulation of heme oxygenase-1. Toxicology: pulmonary irritant, mitochondrial poison
Inflammatory effects Dose-dependently proinflammatory or anti-inflammatory and anti-apoptotic effects
Table adapted from [1].pressure of approximately 30 mmHg), it exerted vaso-
constrictor effects at a 200 μM oxygen concentration (that is,
aan oxygen partial pressure of approximately 150 mmHg)
[56]. Finally, the H2S-related inhibition of oxidative phos-
phorylation also contributes to the vasodilatation [57].
Owing to its SH group that allows reduction of disulfide
bonds and radical scavenging, H2S also exerts biological
effects as an antioxidant [9], in particular as an endogenous
peroxynitrite scavenger [58], which is consistent with its
cytoprotective effects in various cell-based experiments
[59,60]. In this context the effect of H2S on intracellular signal
pathways assumes particular importance: in LPS-stimulated
macrophages, pretreatment with physically dissolved gaseous
H2S or the H2S-donor NaHS was affiliated with diminished
activation of the nuclear transcription factor NF-κB and
inhibition of the inducible isoform of the NO synthase. This
effect coincided with increased expression of heme
oxygenase-1, and co-incubation with carbon monoxide
mimicked the cytoprotection exerted by H2S [61].
Conflicting data are available on the effects of H2S on other
intracellular signal transduction pathways; for example, the
mitogen-activated protein kinase pathway and the phospha-
tidyinositol-3-kinase/Akt pathway [20,61-65]. Depending on
the cell lines used, both inhibitory [20] and activating
[36,61,64] effects on p38 mitogen-activated protein kinase
were reported, whereas H2S seems not to affect the stress-
activated protein kinase c-Jun N-terminal kinase [61,65]. In
contrast, activation of the extracellular signal-regulated kinase
1/2 pathway has been implicated in the H2S-related ischemic
preconditioning [48], both its proinflammatory [63,65] and
anti-inflammatory [20,61] effects, as well as in the induction
of apoptosis [62]. While the influence of H2S on extracellular
signal-regulated kinase seems to be rather comprehensible
[25], studies exploring the effect on downstream pathways
result in conflictive statements.
Jeong and colleagues reported that H2S enhances NO
production and inducible NO synthase expression by
potentiating IL-1β-induced NF-κB in vascular smooth muscle
cells [63], which is consistent with the H2S-induced NF-κB
activation and subsequent proinflammatory cytokine produc-
tion in IFNγ-primed monocytes [65]. Nevertheless, any H2S
effect on NF-κB and its transcription-regulated mediators (for
example, inducible NO synthase, cytokines and apoptotic
factors) may be cell-type dependent and stimulus dependent.
In fact, in addition to the above-mentioned decreased NF-κB
activation and inducible NO synthase expression in LPS-
stimulated macrophages [61], H2S administration also attenu-
ated inducible NO synthase expression, NO production, as
well as TNFα secretion in microglia exposed to LPS [20].
In the context of these contradictory findings, the doses of
the H2S donors administered may assume particular impor-
tance. Even the physiologically relevant concentrations
[36,64] might have to be reconsidered due to overestimation
of basal H2S levels: murine plasma sulfide levels are reported
between 10 and 34 μM [21,22], and are increased up to 20
to 65 μM after endotoxin injection [21] or cecal ligation and
puncture [22]. A reduction of plasma sulfide concentration
from 50 μM to ~25 μM, finally, was reported in patients with
coronary heart disease [1], whereas plasma sulfide levels
increased from 44 to 150 μM in patients with sepsis [21]. It
should be noted, however, that the distinct techniques used
by various groups to determine sulfide levels may account for
the marked variability in the baseline values reported. The
various derivatization methods, which are inherent to the
analytic procedures, are likely to liberate sulfide from its
bound forms so that the exact amount of free and bioavailable
sulfide may be lower than frequently reported [66]. In fact,
Mitsuhashi and colleagues reported that the blood sulfite
concentrations (that is, the product of mitochondrial sulfide
oxidation) were 3.75 ± 0.88 μM only in patients with pneu-
monia (versus 1.23 ± 0.48 μM in healthy control individuals)
[67]. Infusing 2.4 and 4.8 mg/kg/hour in anesthetized and
mechanically ventilated pigs over 8 hours resulted in
maximum blood sulfide levels of 2.0 and 3.5 μM, respectively
(baseline levels 0.5 to 1.2 μM) in our experiments [16].
Metabolic effects of H2S: induction of
suspended animation
Suspended animation is a hibernation-like metabolic status
characterized by a marked yet reversible reduction of energy
expenditure, which allows nonhibernating species to sustain
environmental stress, such as extreme changes in tempera-
ture or oxygen deprivation [41,68].
In landmark work, the Roth’s group provided evidence that
inhaled H2S can induce such a suspended animation
[40,41]: in awake mice, breathing 80 ppm H2S caused a
dose-dependent reduction of both the respiratory rate and
the heart rate as well as of oxygen uptake and carbon dioxide
production, which was ultimately associated with a drop in
body core temperature to levels ~2°C above ambient
temperature [40]. All these effects were completely reversible
after H2S washout, and thereafter animals presented with a
totally normal behavior. A follow-up study confirmed these
observations, and the authors demonstrated using telemetry
and echocardiography that the bradycardia-related fall in
cardiac output coincided with an unchanged stroke volume
and blood pressure. These physiologic effects of inhaled H2S
were present regardless of the body core temperature
investigated (27°C and 35°C) [69].
It is noteworthy that anesthesia may at least partially blunt the
myocardial effect of inhaled H2S. In mechanically ventilated
mice instrumented with left ventricular pressure volume
conductance catheters and assigned to 100 ppm inhaled
H2S, we found that hypothermia alone (27°C) but not normo-
thermic H2S inhalation (38°C) decreased the cardiac output
due to a fall in heart rate, whereas both the stroke volume as
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remained unaffected (Table 2) [70]. Interestingly, inhaled H2S
in combination with hypothermia, however, was concomitant
with the least stimulation of oxygen flux induced by addition of
cytochrome c during state 3 respiration with combined
complex I and complex II substrates (Figure 1) [71]. Since
stimulation by cytochrome c should not occur in intact
mitochondria, this finding suggests better preservation of
mitochondrial integrity under these conditions [72].
In good agreement with the concept that a controlled
reduction in cellular energetic expenditure would allow main-
tenance of ATP homoeostasis [41] and thus of improving
outcome during shock states due to preserved mitochondrial
function [73,74], the group of Roth and colleagues subse-
quently demonstrated that pretreatment with inhaled H2S
(150 ppm) for only 20 minutes markedly prolonged survival
without any apparent detrimental effects for mice exposed to
otherwise lethal hypoxia (5% oxygen) [75] and for rats
undergoing lethal hemorrhage (60% of the calculated blood
volume over 40 minutes) [8]. It is noteworthy that in the latter
study the protective effect was comparable when using either
inhaled H2S or a single intravenous bolus of Na2S [75]:
parenteral sulfide administration has a number of practical
advantages (ease of administration, no need for inhalation
delivery systems, no risk of exposure to personnel, no issues
related of the characteristic odor of H2S gas) and, in
particular, avoids the pulmonary irritant effects of inhaled
H2S, which can be apparent even at low inspiratory gaseous
concentrations [76]. Finally, it is noteworthy that hypothermia
is not a prerequisite of H2S-related cytoprotection during
hemorrhage: the H2S donor NaHS improved hemodynamics,
attenuated metabolic acidosis, and reduced oxidative and
nitrosative stress in rats subjected to controlled hemorrhage
at a mean blood pressure of 40 mmHg (Figure 2) [9].
The clinical relevance of murine models may be questioned
because, due to their large surface area/mass ratio, rodents
can rapidly drop their core temperature [77]. In fact, other
authors failed to confirm the metabolic effect of inhaled H2S
in anesthetized and mechanically ventilated piglets (body
weight ~6 kg) or in H2S-sedated and spontaneously breath-
ing sheep (body weight ~74 kg) exposed to up to 80 or
60 ppm H2S, respectively [78,79]. These findings may be
due to the dosing or timing of H2S, and are in contrast to
recent data from our own group: in anesthetized and
mechanically ventilated swine (body weight ~45 kg) that
underwent transient thoracic aortic balloon occlusion,
infusing the intravenous H2S donor Na2S over 10 hours
reduced the heart rate and cardiac output without affecting
the stroke volume, thereby reducing oxygen uptake and
carbon dioxide production and, ultimately, core temperature
[16]. The metabolic effect of H2S coincided with an attenua-
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Table 2
Cardiac effects of inhaled H2S in anesthetized and mechanically ventilated mice during normothermia and hypothermia
Control, 38°C H2S, 38°C Control, 27°C H2S, 27°C
Heart rate (beats/min) 350 (289 to 437) 324 (274 to 387) 112 (96 to 305)* 116 (96 to 327)*
Mean arterial pressure (mmHg) 62 (57 to 72) 60 (57 to 65) 45 (37 to 63)* 48 (41 to 59)*
Stroke volume (μl) 33 (19 to 62) 29 (23 to 53) 27 (21 to 39) 25 (20 to 32)
Ejection fraction (%) 45 (38 to 55) 40 (35 to 48) 50 (37 to 57) 47 (35 to 54)
End-diastolic pressure (mmHg) 16 (12 to 18) 15 (12 to 16) 15 (11 to 22) 14 (11 to 18)
Cardiac effects of inhaled hydrogen sulfide (H2S) (100 ppm over 5 hours) in anesthetized and mechanically ventilated mice instrumented with left
ventricular pressure volume conductance catheters during normothermia (38°C) and hypothermia (27°C) [62]. Data presented as median (range),
n = 8 in each group. *P <0.05 versus control, 38°C.
Figure 1
Cytochrome c-stimulated mitochondrial oxygen flux in livers from
anesthetized and mechanically ventilated mice. Ratio of mitochondrial
oxygen flux in homogenized livers from anesthetized and mechanically
ventilated mice after addition in relation to before addition of
cytochrome c. Since stimulation by cytochrome c should not occur in
intact mitochondria, the smallest value (that is, a ratio close to 1.00)
suggests preservation of mitochondrial integrity. Animals were
subjected to inhaled hydrogen sulfide (H2S) (100 ppm over 5 hours) or
vehicle gas during normothermia (38°C) and hypothermia (27°C) [63].
Data presented as mean ± standard deviation, n = 8 in each group.
#P <0.05 versus control, 38°C.tion of the early reperfusion-related hyperlactatemia –
suggesting a reduced need for anaerobic ATP generation
during the ischemia period – and an improved noradrenaline
responsiveness, indicating both improved heart function and
vasomotor response to catecholamine stimulation [16].
H2S-induced cytoprotection during
ischemia–reperfusion
Deliberate hypothermia is a cornerstone of the standard
procedures to facilitate neurological recovery after cardiac
arrest and to improve postoperative organ function after
cardiac and transplant surgery. Consequently, several
authors investigated the therapeutic potential of H2S-induced
suspended animation after ischemia–reperfusion injury – and
H2S protected the lung [14], the liver [12], the kidney
(Figure 3) [17,80], and, in particular, the heart [10,11,13,15,
18,62,81-83]. H2S administered prior to reperfusion there-
fore limited the infarct size and preserved left ventricular
function in mice [10] and in swine [11].
While these findings were obtained without induction of
hypothermia, preserved mitochondrial function documented
by an increased complex I and complex II efficiency assumed
major importance for the H2S-induced cytoprotection [10].
The important role of preserved mitochondrial integrity was
further underscored by the fact that 5-hydroxydeconoate,
which is referred to as a mitochondrial potassium-dependent
ATP-channel blocker, abolished the anti-apoptotic effects of
H2S [18]. Clearly, anti-inflammatory and anti-apoptotic effects
also contributed to the improved postischemic myocardial
function: treatment with H2S was associated with reduced
myocardial myeloperoxidase activity and an absence of the
increase in the IL-1β levels (that is, attenuated tissue inflam-
mation [10,18]), as well as complete inhibition of thrombin-
induced leukocyte rolling, a parameter for leukocyte–endo-
thelium interaction [10]. Moreover, the ischemia–reperfusion-
induced activation of p38 mitogen-activated protein kinase, of
c-Jun N-terminal kinase and of NF-κB was also attenuated by
H2S [18]. Finally, H2S exerted anti-apoptotic effects as
shown by reduced TUNEL staining [10,11] and by expression
of cleaved caspase-9 [18], caspase-3 [10,11], poly-ADP-
ribose-polymerase [11] and the cell death-inducing proto-
oncogene c-fos [13].
Controversial role of H2S in animal models of
inflammation
Despite the promising data mentioned above, it is still a
matter of debate whether H2S is a metabolic mediator or a
toxic gas [84] – particularly given the rather controversial
findings on the immune function reported in various models of
systemic inflammation. In fact, H2S exerted both marked pro-
inflammatory effects [19,21-25,27,85] and anti-inflammatory
effects [9,10,18,20,28-30]. Studies using inhibitors of endo-
genous H2S production such as PAG demonstrated pro-
nounced proinflammatory effects of H2S: PAG attenuated
organ injury, blunted the increase of the proinflammatory
cytokine and chemokine levels as well as the myeloperoxi-
dase activity in the lung and liver, and abolished leukocyte
activation and trafficking in LPS-induced endotoxemia
[19,21] or cecal ligation and puncture-induced sepsis [22-
25,86]. In good agreement with these findings, the H2S donor
NaHS significantly aggravated this systemic inflammation
[21-25,86]. Although similar results were found during
caerulin-induced pancreatitis [27,87], the role of H2S during
systemic inflammatory diseases is still a matter of debate.
Zanardo and colleagues reported reduced leukocyte
infiltration and edema formation using the air pouch and
carrageenan-induced hindpaw edema model in rats injected
with the H2S donors NaHS and Na2S [30]. Moreover, in mice
with acute lung injury induced by combined burn and smoke
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Figure 2
Hydrogen sulfide-related hemodynamic effects in rats subjected to
hemorrhage and subsequent retransfusion. Time course of the
difference in (a) mean blood pressure (ΔMAP) and (b) carotid blood
flow (ΔCBF) in rats subjected to 60 minutes of hemorrhage (MAP 40
mmHg) and subsequent retransfusion of shed blood. Ten minutes prior
to retransfusion, animals received vehicle (n = 11; open circles) or the
hydrogen sulfide donor sodium hydrogen sulfide (bolus 0.2 mg/kg, n =
11; closed circles) [9]. Data presented as mean (standard deviation).
#P <0.05 versus controls.inhalation, a single Na2S bolus decreased tissue IL-1β levels,
increased IL-10 levels, and attenuated protein oxidation in the
lung, which ultimately resulted in markedly prolonged survival
[28].
Variable dosing and timing make it difficult to definitely
conclude on the proinflammatory and/or anti-inflammatory
effects of H2S: while the median sulfide lethal dose in rats
has been described to be approximately 3 mg/kg intra-
venously [1], studies in the literature report on doses ranging
from 0.05 to 5 mg/kg. In addition, there are only a small
number of reports on continuous intravenous infusion rather
than bolus administration. Finally, the role of the suspended
animation-related hypothermia per se remains a matter of
debate. While some studies report that spontanoues hypo-
thermia and/or control of fever may worsen the outcome [88],
other authors describe decreased inflammation [89] and
improved survival after inducing hypothermia in sepsis [90].
We found in anesthetized and mechanically ventilated mice
undergoing sham operation for surgical instrumentation that
normothermic H2S (100 ppm) inhalation (38°C) over 5 hours
and hypothermia (27°C) alone comparably attenuated the
inflammatory chemokine release (monocyte chemotactic
protein-1, macrophage inflammatory protein-2 and growth-
related oncogen/keratinocyte-derived chemokine) in the lung
tissue. While H2S did not affect the tissue concentrations of
TNFα, combining hypothermia and inhaled H2S significantly
decreased tissue IL-6 expression (Table 3) [91].
Conclusions
Based on the concept that multiorgan failure secondary to
shock, inflammation and sepsis may actually be an adaptive
hypometabolic reponse to preserve ATP homoeostasis [92] –
such as has been demonstrated for the septic heart [93] –
and thus represent one of the organism’s strategies to survive
under stress conditions, the interest of inducing a hiber-
nation-like suspended animation with H2S is obvious. Investi-
gations have currently progressed most for the treatment of
myocardial ischemia [94]. It must be underscored, however,
that only a relatively small proportion of the published studies
was conducted in clinically relevant large animal models
[11,16,95], and, furthermore, that the findings reported are
controversial [16,78,79].
Moreover, several crucial issues warrant further investigation
before the clinical application of this concept. First, the role of
hypothermia for any suspended animation-related organ
protection is well established [96], but its impact remains a
matter of debate for H2S-related organ protection. Clearly, in
the rodent studies [10,12,18,28], any cytoprotective effect
Critical Care    Vol 13 No 3 Wagner et al.
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Figure 3
Hydrogen sulfide attenuation of oxidative DNA damage in the kidney
after organ ischemia–reperfusion. Oxidative DNA damage (tail moment
in the alkaline version of the comet assay [89]) in kidney tissue
biopsies prior to (left panel) and after 2 hours of organ ischemia and 8
hours of reperfusion (right panel) in control swine (n = 7; open box
plots) and in animals treated with the hydrogen sulfide donor sodium
disulfide (Na2S) (n = 8; grey box plots). Renal ischemia was induced
by inflating the balloon of an intra-aortic catheter positioned at the
renal artery orifices. Na2S infusion was infused before kidney ischemia
(2 mg/kg/hour over 2 hours) as well as during the first 4 hours of
reperfusion (1 mg/kg/hour) [72]. Data presented as median (quartiles,
range). #P <0.05 versus before ischemia, §P <0.05 versus control.
Table 3
Lung tissue concentrations of inflammatory chemokines after inhaling H2S during normothermia or hypothermia
Control, 38°C H2S, 38°C Control, 27°C H2S, 27°C
TNFα (pg/mg protein) 67 (52 to 90) 75 (60 to 88)  76 (54 to 88) 71 (60 to 81)
IL-6 (pg/mg protein) 449 (264 to 713) 366 (252 to 483) 338 (140 to 500) 260 (192 to 339)*
MCP-1 (pg/mg protein) 194 (102 to 280) 114 (77 to 138)* 99 (68 to 168)* 106 (48 to 150)*
MIP-2 (pg/mg protein) 613 (278 to 1049) 284 (214 to 357)* 306 (231 to 376)* 283 (248 to 373)*
KC (pg/mg protein) 435 (268 to 602) 296 (255 to 332)* 309 (217 to 401)* 329 (301 to 366)*
Lung tissue concentrations of monocyte chemotactic protein-1 (MCP-1), macrophage-inflammatory protein-2 (MIP-2), growth-related
oncogen/keratinocyte-derived chemokine (KC), TNFα, and IL-6 after inhaling hydrogen sulfide (H2S) (100 ppm over 5 hours) during normothermia
(38°C) or hypothermia (27°C) [83]. Data presented as median (range), n = 5 in each group. *P <0.05 versus control, 38°C.was apparent without a change in core body temperature, but
localized metabolic effects cannot be excluded [10]. In
addition, the role of any H2S-related hypothermia remains
controversial in the context of systemic inflammation [88].
Second, similar to the friend and foe character of NO, no
definitive conclusions can be made as to whether H2S exerts
proinflammatory or anti-inflammatory properties [1,6,85].
Finally, in addition to the question of dosing and timing (for
example, bolus administration versus continuous intravenous
infusion), the preferred route of H2S administration remains to
be settled: while inhaling gaseous H2S probably allows easily
titrating target blood concentrations, it is well established that
this method can also directly cause airway irritation [76].
While H2S-induced suspended animation in humans to date
may still be referred to as science fiction, there are ample
promising preclinical data that this approach is a fascinating
new therapeutic perspective for the management of shock
states that merits further investigation.
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